Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQB3702 in Hematologic Tumors
NCT05610202Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3702 in hematologic malignancy, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum tolerated dose up to 104 weeks, Dose limited toxicity up to 104 weeks and 1 more. Status: unknown.
02
Drugs
TQB3702
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05610202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610202.